Publications

@article{Mahmoud2022-ls,

title = {Challenges for Triple Negative Breast Cancer treatment: 

 Defeating heterogeneity and cancer stemness},

author = {Rinad Mahmoud and Paloma Ord\'{o}\~{n}ez-Mor\'{a}n and Cinzia Allegrucci},

year  = {2022},

date = {2022-09-01},

journal = {Cancers (Basel)},

volume = {14},

number = {17},

pages = {4280},

publisher = {MDPI AG},

abstract = {The Triple Negative Breast Cancer (TNBC) subtype is known to 

 have a more aggressive clinical course compared to other breast 

 cancer subtypes. Targeted therapies for this type of breast 

 cancer are limited and patients are mostly treated with 

 conventional chemo- and radio-therapies which are not specific 

 and do not target resistant cells. Therefore, one of the major 

 clinical challenges is to find compounds that target the 

 drug-resistant cell populations which are responsible for 

 reforming secondary tumours. The molecular profiling of the 

 different TNBC subtypes holds a promise for better defining 

 these resistant cells specific to each tumour. To this end, a 

 better understanding of TNBC heterogeneity and cancer stemness 

 is required, and extensive genomic analysis can help to 

 understand the disease complexity and distinguish new molecular 

 drivers that can be targeted in the clinics. The use of 

 persister cancer cell-targeting therapies combined with other 

 therapies may provide a big advance to improve TNBC patients' 

 survival.},

keywords = {Differentiation, drug resistance, persister cells, phenotype, stemness, triple negative breast cancer, tumour heterogeneity},

pubstate = {published},

tppubtype = {article}

}